Physician profile
Daniel R Silbiger
NPI 1639490469
$4,996.82
in general payments reported to CMS, 2019-2025
36 companies · $3,630 in 2025
The $3,630 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $753 · 2020: $257 · 2021: $53.83 · 2022: $225 · 2024: $77.97 · 2025: $3,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,505 · Food and Beverage: $125 · Education: $77.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,505.00 |
| Food and Beverage | $125.00 |
| Education | $77.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,386.99 | 2019-2025 | |
| Gilead Sciences, INC. | $1,171.92 | 2021-2025 | Trodelvy |
| Novocure Gmbh | $200.00 | 2022 | |
| Beone Medicines USA, INC. | $125.00 | 2025 | Brukinsa |
| Eisai INC. | $114.49 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $111.49 | 2019 | |
| Seagen INC. | $77.97 | 2024 | |
| Exelixis INC. | $65.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $64.38 | 2019-2020 | |
| Amgen INC. | $60.33 | 2019 | |
| Lilly USA, LLC | $56.60 | 2019-2020 | |
| Astellas Pharma US INC | $50.66 | 2019-2020 | |
| Genzyme Corporation | $44.76 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $42.46 | 2019 | |
| Shionogi INC | $39.97 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $35.79 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.49 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $31.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $27.13 | 2019 | |
| Daiichi Sankyo INC. | $24.74 | 2022 | |
| Emd Serono, INC. | $22.77 | 2019-2020 | |
| Tesaro, INC. | $21.00 | 2019 | |
| Celgene Corporation | $19.19 | 2020 | |
| Kite Pharma, INC. | $17.22 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $16.67 | 2019 | |
| Alexion Pharmaceuticals, INC. | $14.02 | 2019 | |
| Janssen Biotech, INC. | $13.13 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.05 | 2020 | |
| Sun Pharmaceutical Industries INC. | $12.86 | 2019 | |
| Epizyme, INC. | $12.52 | 2020 | |
| Beigene USA, INC. | $12.50 | 2020 | |
| Jazz Pharmaceuticals INC. | $11.61 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.60 | 2019 | |
| Octapharma USA, INC. | $11.23 | 2019 | |
| Portola Pharmaceuticals, LLC | $11.20 | 2020 | |
| Clovis Oncology, INC. | $10.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Silbiger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.